AAN 2023 | MOG-IgA characterizes a subgroup of patients with central nervous system demyelination

Anne-Katrin Pröbstel, MD, University Hospital of Basel, University of Basel, Basel, Switzerland, describes the results of a study designed to assess the frequency of myelin oligodendrocyte glycoprotein (MOG) IgA in patients with central nervous system demyelination and link this to clinical phenotypes. The study screened for MOG-IgA, IgG, and IgM in 1339 patients with demyelinating diseases, and 110 healthy controls. Of the 18 patients with isolated MOG-IgA, 6% had double seronegative NMOSD, 2% had ‘other’ demyelinating diseases, and 1% had multiple sclerosis (MS), showing a strong link to neuromyelitis optica spectrum disorder (NMOSD). These patients most frequently had myelitis, followed by brainstem syndrome. Of the MOG-IgA patients who had MS, 38% had type-II oligoclonal bands, which was decreased when compared to MS patients without MOG-IgA. This shows that MOG-IgA patients have a specific clinical phenotype that overlaps with NMOSD. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.